Faster Approval Process Contributing to Biotech Industry's Success in 2012
September 12 2012 - 8:20AM
Marketwired
Despite concerns of a global economic slowdown the Biotech Industry
has impressed investors with strong gains in 2012. Patent
expirations, favorable legislation, and a faster review process
have been some of the contributing factors for the industry's
current boom. The Paragon Report examines investing opportunities
in the Biotechnology Industry and provides equity research on
AEterna Zentaris Inc. (NASDAQ: AEZS) and Galena Biopharma Inc.
(NASDAQ: GALE).
Access to the full company reports can be found at:
www.ParagonReport.com/AEZS www.ParagonReport.com/GALE
The Food and Drug Administration Safety and Innovation Act
(FDASIA) was signed into law on July 9, 2012 by President Obama.
The law allows the FDA to collect "user fees" to help fund reviews
of innovator drugs, medical devices, generic drugs and
biosimilars.
"The legislation will enhance the development and review of
innovative new therapies through increased transparency and
scientific dialogue, advancements in regulatory science and
strengthened post-market review. It will also increase the Food and
Drug Administration's (FDA) access to external expertise to improve
the drug review process," Biotechnology Industry Organization (BIO)
President and CEO Jim Greenwood said in a statement.
Paragon Report releases regular market updates on the
Biotechnology Industry so investors can stay ahead of the crowd and
make the best investment decisions to maximize their returns. Take
a few minutes to register with us free at www.ParagonReport.com and
get exclusive access to our numerous stock reports and industry
newsletters.
Aeterna Zentaris is an oncology and endocrinology drug
development company currently investigating treatments for various
unmet medical needs. The Company's pipeline encompasses compounds
at all stages of development, from drug discovery through to
marketed products. The first patient was recently recruited for a
Phase 2A trial with its ghrelin agonist, AEZS-130 in patients with
cancer cachexia.
Galena Biopharma is focused on discovering, developing and
commercializing innovative therapies addressing major unmet medical
needs using targeted biotherapeutics. The company on July 18, 2012
was issued a patent for their product candidate, NeuVax, a HER2/neu
peptide vaccine. Shares of the company have more than tripled in
2012.
The Paragon Report has not been compensated by any of the
above-mentioned publicly traded companies. Paragon Report is
compensated by other third party organizations for advertising
services. We act as an independent research portal and are aware
that all investment entails inherent risks. Please view the full
disclaimer at: http://www.paragonreport.com/disclaimer
Add to Digg Bookmark with del.icio.us Add to Newsvine
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Jul 2023 to Jul 2024